GlaxoSmithKline plc
News and overview for GlaxoSmithKline plc
SuperGen, GlaxoSmithKline sign collaboration deal - MarketWatch
MarketWatch | 29 days 8 hours 9 minutes ago
HSBC Holdings to sell some HSS France ops
FDA approves GlaxoSmithKline renal cancer drug - MarketWatch
MarketWatch | 35 days 17 hours 11 minutes ago
GSK
GlaxoSmithKline pulls swine flu vaccines in Canada
Boston Globe, The | 3 hours 49 minutes ago
LONDONPharmaceuticals company GlaxoSmithKline PLC said Tuesday it has advised medical staff in Canada to not use one batch of swine flu vaccines in case they trigger life-threatening allergies.
Reportlinker Adds GlaxoSmithKline plc: PharmaVitae Profile [Press Release]
PRNewswire | 20 days 20 hours 23 minutes ago
...reportlinker.com/p0157541/GlaxoSmithKline-plc-PharmaVitae-Profile...2002-14 59 Figure 16: GlaxoSmithKline prescription pharmaceutical...reportlinker.com/p0157541/GlaxoSmithKline-plc-PharmaVitae-Profile...
GlaxoSmithKline pulls application for new drug use
Boston Globe, The | 22 hours 9 minutes ago
TRENTON, N.J.British drugmaker GlaxoSmithKline PLC said Monday it is temporarily withdrawing its application for U.S. approval of a drug to prevent prostate cancer.
Britain's GlaxoSmithKline pulls application to sell enlarged prostate drug for blocking cancer
Sun (Baltimore), The | 22 hours 56 minutes ago
British drugmaker GlaxoSmithKline PLC said Monday it is temporarily withdrawing its application for U.S. approval of a drug to prevent prostate cancer.
GlaxoSmithKline Halts H1N1 Vaccinations In Canada
Modern Materials Handling | 1 day 3 hours 45 minutes ago
WASHINGTON (Kyodo) -- British drug maker GlaxoSmithKline Plc. is suspending the use of 170,000 doses of its new H1N1 influenza vaccine in Canada given a higher-than-usual rate of reported side effects, Canadian media reported Monday.
Zacks Analyst Blog Highlights: GlaxoSmithKline plc, Sanofi-Aventis, Novartis, Baxter International and AstraZeneca [Press Release]
Business Wire | 7 days 20 hours 23 minutes ago
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: GlaxoSmithKline plc (NYSE: GSK), Sanofi-Aventis (NYSE: SNY), Novartis (NYSE: NVS), Baxter International (NYSE: BAX) and AstraZeneca (NYSE: AZN).
Human Genome Sciences and GlaxoSmithKline Announce Positive Results in Second of Two Phase 3 Trials of BENLYSTA in Systemic Lupus Erythematosus [Press Release]
Business Wire | 22 days 6 hours 23 minutes ago
Human Genome Sciences, Inc. (Nasdaq:HGSI) and GlaxoSmithKline PLC (GSK) today announced that BENLYSTA™ (belimumab) met the primary endpoint in BLISS-76, the second of two pivotal Phase 3 trials in seropositive patients with systemic lupus erythematosus (SLE). BLISS-76 study results through 52 weeks showed that belimumab 10 mg/kg plus standard of care achieved a statistically significant improvement in patient response rate as measured by the SLE Responder Index at Week 52, compared with place...
Britain's GlaxoSmithKline pulls application to sell enlarged prostate drug for blocking cancer -- South Florida Sun-Sentinel.com
Sun-Sentinel (Fort Lauderdale, Fla.) | 23 hours 43 minutes ago
TRENTON, N.J. (AP) — British drugmaker GlaxoSmithKline PLC says it's withdrawing its application for U.S. approval of a drug to prevent prostate cancer .
Research and Markets: Opportunity Analysis of H1N1 (swine flu) Vaccination Market - The Global H1N1 Influenza Vaccine Market is Estimated to be of 676 Million in 2009 [Press Release]
Business Wire | 1 day 6 hours 23 minutes ago
Research and Markets (http://www.researchandmarkets.com/research/18be8b/opportunity_analys) has announced the addition of the "Opportunity Analysis of H1N1 (swine flu) Vaccination Market" report to their offering.
Nabi, Glaxo agree nicotine vaccine licensing deal - MarketWatch
MarketWatch | 8 days 7 hours 5 minutes ago
Nabi, Glaxo agree nicotine vaccine licensing deal
Human Genome Sciences and GlaxoSmithKline Announce Positive Results in Second of Two Phase 3 Trials of BENLYSTA(TM) in Systemic Lupus Erythematosus [Press Release]
MarketWire | 22 days 7 hours 22 minutes ago
ROCKVILLE, MD and LONDON -- (Marketwire) -- 11/02/09 -- Human Genome Sciences, Inc. (NASDAQ: HGSI) and GlaxoSmithKline PLC (GSK) today announced that
FDA warns against taking Plavix with Prilosec - MarketWatch
MarketWatch | 6 days 23 hours 56 minutes ago
Prilosec, also known as omeprazole or Losec, is marketed by AstraZeneca plc /quotes/comstock/13*!azn/quotes/nls/azn (AZN 45.23, -0.97, -2.10%) .
Research and Markets: Alzheimer's and Parkinson's Diseases - a Global Update of Market Trends & Opportunities [Press Release]
Business Wire | 5 days 5 hours 23 minutes ago
Research and Markets (http://www.researchandmarkets.com/research/5f3158/alzheimers_and_pa) has announced the addition of the "Alzheimer's and Parkinson's Diseases - A Global Update of Market Trends & Opportunities" report to their offering.
Sign up for AANP SmartBrief
Company Overview
| Company: | GlaxoSmithKline plc |
|---|---|
| Industry: | Pharmaceuticals Manufacturers |
| Website: | http://www.gsk.com |
GlaxoSmithKline (GSK) calms your nerves and helps you breathe easier. One of the top five pharmaceutical firms in the world, GSK's top sellers include central nervous system therapies, respiratory drugs, and antiviral therapies, as well as vaccines. The company's top product is asthma medication Advair, which combines two of the company's other products, Flovent and Serevent. Other bestsellers include herpes treatment Valtrex, epilepsy treatment Lamictal, antidepressant Paxil, migraine therapy Imitrex, and antibiotic Augmentin. The company's consumer products include Tums for sour stomachs, dental care products Aquafresh and Sensodyne, and smoking-cessation products NicoDerm and Nicorette.
Key Numbers
| Sales in U.S. Dollars (mil.) | 35,244.602 (2008) |
|---|---|
| One-year % Growth in Sales | -22.3 (2008) |
| Net Income in U.S. Dollars (mil.) | 6,819.7 (2008) |
| One-year % Growth in Net Income | -34.5 (2008) |
| Number of Employees | 99,003 (2008) |
| One-year % Growth in Number of Employees | -3.9 (2008) |
| Fiscal Year-End | December |